Shire files to block infringement

Biopharmaceutical company Shire has filed a lawsuit for patent infringement and breach of contract against their US rival Watson Pharmaceuticals which intends to produce generic versions of the Aderall XR drug before its patent expires. The lawsuit follows Watson’s new drug application with the US Food and Drug Administration to market generic versions of Aderall XR which treats attention deficit and hyperactivity disorder.